Ascletis Pharma, Inc. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
No of Months
12
12
12
12
12
12
Profit Before Tax
-320.00
-137.00
-339.00
-218.00
-219.00
-95.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
17.00
38.00
39.00
-12.00
11.00
-9.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
-236.00
-159.00
-165.00
-177.00
-95.00
-84.00
Cash Flow from Investing Activities
930.00
165.00
-1,508.00
-330.00
148.00
682.00
Cash Flow from Financing Activities
-112.00
-90.00
-1.00
-37.00
-24.00
-54.00
Net Cash Inflow / Outflow
581.00
-81.00
-1,539.00
-582.00
-94.00
581.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
2.00
136.00
-36.00
-123.00
37.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in HKD Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Ascletis Pharma, Inc.
Figures in Million
consolidated Cash Flow Results
Change(HKD)
Change(%)
Profit Before Tax
-320.564873946376
320.713412612799
-640.00
-199.95%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
17.5156361756584
-35.7175860436221
52.00
149.04%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
-236.528852361546
368.492988904282
-604.00
-164.19%
Cash Flow from Investing Activities
930.101423292391
223.120256101294
707.00
316.86%
Cash Flow from Financing Activities
-112.225841489944
-697.731653590693
585.00
83.92%
Net Cash Inflow / Outflow
581.769576739478
-102.580586187025
683.00
667.13%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0.422847298576712
3.53782239809183
-3.00
-88.05%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -48.48% vs 3.84% in Dec 2023
Dec'24
Dec'23
Change(%)
Cash Flow from Operating Activities
-236.53
-159.30
-48.48%






